Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| 44.77 | |
| 46.49 | |
| - | |
| 46.9 | |
| 44.645 | |
| 9.6-50.185 | |
| 3 028 M | |
| 64 584 K | |
| 88 550 K | |
| -0.58 | |
| 2.222 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
A month has gone by since the last earnings report for Kymera Therapeutics, Inc. (KYMR). Shares have added about 10.9% in that time frame, outperforming the S&P 500. Will the recent positive trend co...
Kymera Therapeutics, Inc. WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molec...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
